Vir Biotechnology Inc. (VIR) Tops Q4 EPS by 22c, Beats on Revenue

Vir Biotechnology Inc. (NASDAQ: VIR) reported Q4 EPS of ($0.86), $0.22 better than the analyst estimate of ($1.08). Revenue for the quarter came in at $16.8 million versus the consensus estimate of $12.07 million.

For earnings history and earnings-related data on Vir Biotechnology Inc. (VIR) click here.

You May Also Be Interested In

• John Wiley & Sons, Inc. (WLY) Tops Q1 EPS by 4c ; Offers Guidance
• Samsara Inc (IOT) Tops Q2 EPS by 4c, Beats on Revenue; Offers Q3 Guidance
• Oxford Industries (OXM) Tops Q2 EPS by 4c; offers guidance